| Literature DB >> 36192691 |
Abdulwahab Teflischi Gharavi1, Niloofar Asadi Hanjani1, Elaheh Movahed2, Mohammad Doroudian3.
Abstract
Macrophages are influential members of the innate immune system that can be reversibly polarized by different microenvironment signals. Cell polarization leads to a wide range of features, involving the migration, development, and organization of the cells. There is mounting evidence that macrophage polarization plays a key role in the initiation and development of a wide range of diseases. This study aims to give an overview of macrophage polarization, their different subtypes, and the importance of alternatively activated M2 macrophage and classically activated M1 macrophage in immune responses and pathological conditions. This review provides insight on the role of exosomes in M1/M2-like macrophage polarization and their potential as a promising therapeutic candidate.Entities:
Keywords: Exosomes; Inflammation; Macrophage polarization; Macrophages
Mesh:
Year: 2022 PMID: 36192691 PMCID: PMC9528143 DOI: 10.1186/s11658-022-00384-y
Source DB: PubMed Journal: Cell Mol Biol Lett ISSN: 1425-8153 Impact factor: 8.702
Macrophage subtypes and their characteristic markers and stimuli
| Macrophage types | Suggested roles | Markers | Different stimulator factors | References |
|---|---|---|---|---|
| M1 | Pro-inflammation, microbicidal effect, tumor resistance | IL-6, IL-10 (low), IL-12 (high), iNOS, CD80, CD86, CXCL9, CXCL10, CXCL11, CCL15, CCL20, CCL22, TLR2, TLR4, MHCII, TNF-α | IL-1, IL-6, IL-12, CXCL1-3, CXCL-5, CXCL8-10, CCL2, Type I IFN, IFN-γ, TNF-α, STAT1, iNOS, LPS, M-CSF, NF-κB, IRF5 miR-155, miR-125b, DNMT1, DNMT3b, HDAC3 | [ |
| M2a | Allergy, profibrotic, anti-inflammatory, wound healing | IL-10, IL-1R, IL-27Rα, CCL1, CCL17, CCL18, CCL22, CD11b, CD45, CD206, YM1, RELMα, IGF1, DCIR, Stabilin 1, Factor XIII-A, Ly6C, TREM-2, DC-SIGN | IL-4, IL-10, IL-13, (PPAR-γ) | [ |
| M2b | Th2 activation, immune regulation, promoting infection, tumor progression | IL-6, TNF-α, CD86, SPHK1 | IL-1β, LPS | [ |
| M2c | Immunosuppression, phagocytosis, tissue repair, matrix remodeling | IL-10, CXCL13, CD163, CD206, CXCR4, TGF-β, MerTK, | IL-10, glucocorticoids IL-6, IL-10, TNF-α, TLR, | [ |
| M2d | Tumor progression, angiogenesis, clearance of apoptotic tissue | IL-10, VEGF, TGF-β, | LPS | [ |
CCL, C–C chemokine ligand; CXCL, C–X–C chemokine ligand; CXCR, C–X–C chemokine receptor; DCIR, dendritic cell immunoreceptor; IFN, interferon; IFNγ, interferon-γ; IL, interleukin; IL-1R, IL-1 receptor; IL-27Rα, IL-27 receptor α-chain; iNOS, inducible nitric-oxide synthase; RELMα, resistin-like molecule-α; SPHK1, sphingosine kinase 1; TLR, Toll-like receptor; CD, cluster of differentiation; TGF-β, transforming growth factor-β; STATs, signal transducer and activator of transcription; PPAR-γ, peroxisome proliferator-activated receptor gamma; TNF-α, tumor necrotic factor-α; YM1, chitinase-like protein 3; LPS, lipopolysaccharides; VEGF, vascular endothelial growth factor; ICAM, intercellular adhesion molecule; DC-SIGN, dendritic cell-specific ICAM-grabbing non integrin; IRF5, interferon regulatory factor 5; HDAC3, histone deacetylase 3; MerTK, myeloid epithelial reproductive tyrosine kinase; M-CSF, macrophage-colony-stimulating factor; DNMT, DNA methyl transferase; miRs, microRNAs; NF-κB, nuclear factor-κB; MHCII, major histocompatibility complex II; IGF, insulin-like growth factor; Ly6C, lymphocyte antigen 6 complex; TREM-2, triggering receptor expressed on myeloid cells 2
Fig. 1Macrophage polarization phenotypes and subtypes according to their different characteristics have many roles in immune responses. M1 macrophages have a pro-inflammatory role by their cytokines, but M2 macrophages, which are divided into four subtypes, have many different roles. For example, M2a macrophages play an important role in parasite killing, M2b macrophages function as immune system regulators, M2c macrophages assist in the wound healing process, and M2d macrophages have a pro-angiogenic role and are very important in tumor progression. CCL, C–C chemokine ligand; CXCL, C–X–C chemokine ligand; CXCR, C–X–C chemokine receptor; DCIR, dendritic cell immunoreceptor; IFN, interferon; IFNγ, interferon-γ; IL, interleukin; RELMα, resistin-like molecule-α; SPHK1, sphingosine kinase 1; TLR, Toll-like receptor; CD, cluster of differentiation; TGF-β, transforming growth factor-β; PPAR-γ, peroxisome proliferator-activated receptor gamma; TNF-α, tumor necrotic factor-α; YM1, chitinase-like protein 3; LPS, lipopolysaccharides; VEGF, vascular endothelial growth factor; MerTK, myeloid epithelial reproductive tyrosine kinase; DNMT, DNA methyl transferase; miRs, microRNAs; MHCII, major histocompatibility complex II; IGF, insulin-like growth factor
Fig. 2Mammalian arginine metabolism pathways and M1 and M2 macrophage polarization. Arginine metabolism can be derived via NOS or arginase. NOS, which is expressed in M1 macrophages, causes arginine metabolism to release NO and citrulline, and M2 macrophages synthesize arginase, which causes arginine metabolism to release ornithine and urea. Downstream pathways of ornithine include putrescine, spermidine, and spermine, which hydrolyze products of ODC, SRM, and spermine synthase, respectively. Spermine can be resynthesized to spermidine by SMOX. As shown in the figure, putrescine and spermine downregulate the polarization of the M1 macrophages. Spermidine upregulates M1 macrophage polarization. In the case of M2 macrophage polarization, spermidine and spermine have inhibitor and enhancer effects, respectively. M1 macrophages increase NOS, but M2 macrophages upregulate arginase and ODC. Both arginine metabolic pathways arrest each other. Enzymes are shown by blue boxes and metabolites by yellow boxes, respectively. NOS, nitric oxide synthase; NO, nitric oxide; ODC, ornithine decarboxylase; SRM, spermidine synthase; SMOX, spermine oxidase
Immunomodulatory drugs that target macrophage polarization
| immunomodulatory drugs | Functions | References |
|---|---|---|
| Thapsigargin | Promote M2 polarization | [ |
| Glucocorticoids | Trigger M2 polarization | [ |
| Azithromycin | Promotes polarization from M1 to M2 | [ |
| 5-Aminosalicylates (5-ASAs) | Inhibitory role in macrophage activation and inflammation suppressor | [ |
| [6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine] | Repressed nitric oxide synthase (iNOS) expression | [ |
| Imiquimod | Restore pro-inflammatory of TAMs | [ |
PLX3397, PLX108-01 (pexidartinib) | Deplete macrophages | [ |
| Trabectedin | Deplete macrophages | [ |
CP-690,550 (tofacitinib) | Inhibit modulate gene expression in macrophages | [ |
Hyaluronic acid oligosaccharides | Modulate macrophage polarity | [ |
| Tocilizumab | M1 macrophage suppression | [ |
Clinical trials on macrophage polarization and inflammation
| Status | Study title | Intervention | ClinicalTrials.gov identifier |
|---|---|---|---|
| Recruiting | Treatment of macrophage activation syndrome (MAS) with anakinra | •Drug: kineret •Drug: placebo | NCT02780583 |
| Completed | Effect of liraglutide (Victoza) on inflammation in human adipose tissue and blood | •Drug: Victoza (liraglutide) with dietician monitoring •Other: placebo with dietician monitoring | NCT02650206 |
| Completed | The effect of gut sterilization on macrophage activation in patients with alcoholic hepatitis | •Drug: combined vancomycin and gentamycin and meropenem | NCT03157388 |
| Completed | Macrophage activation markers during sofosbuvir-based treatment regimens of chronic hepatitis C | •Drug: galactose •Procedure: gastroscopy •Procedure: liver biopsy •Procedure: FibroScan •Procedure: liver vein catheterization •Drug: sofosbuvir | NCT02528461 |
| Unknown status | New candidate criteria for diagnosis of macrophage activation syndrome | – | NCT01095146 |
| Completed | Exploration of immunity in Gaucher disease | – | NCT01358188 |
| Completed | A study to investigate the safety and efficacy of emapalumab, an anti-IFN-gamma mAb in patients with systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still’s disease (AOSD) developing macrophage activation syndrome/secondary HLH (MAS/sHLH) | •Drug: emapalumab | NCT03311854 |
| Recruiting | sCD163 in patients with PBC—assessment of disease severity and prognosis | •Other: blood samples, FibroScan, and questionnaires | NCT02924701 |
| Completed | A role for RAGE/TXNIP/inflammasome axis in alveolar macrophage activation during ARDS (RIAMA): a proof-of concept clinical study | •Other: RAGE/TXNIP/inflammasome axis | NCT02545621 |
| Recruiting | sCD163 in patients with PBC—assessment of treatment response | •Other: blood samples •Device: FibroScan •Other: questionnaires •Biological: liver biopsy | NCT02931513 |
| Completed | Downmodulating monocyte activation for HIV-1-associated neurocognitive disorders (HAND) | •Drug: atorvastatin (Lipitor) •Drug: placebo | NCT01600170 |
| Completed | A trial of validation and restoration of immune dysfunction in severe infections and sepsis | •Drug: anakinra •Drug: recombinant human interferon gamma •Drug: placebo | NCT03332225 |
Fig. 3Exosomes are derived from different cells, including MSCs, tumor cells, or other cells that are present in the microenvironment such as macrophages. These exosomes can switch macrophage polarization according to their cargos. MSCs, mesenchymal stromal cells; lncRNA, long noncoding RNAs; miR, microRNAs; circRNA, circular RNA